53 related articles for article (PubMed ID: 20484880)
1. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
Illidge T; Chan C; Counsell N; Morris S; Scarisbrick J; Gilson D; Popova B; Patrick P; Smith P; Whittaker S; Cowan R
Br J Cancer; 2013 Nov; 109(10):2566-73. PubMed ID: 24136145
[TBL] [Abstract][Full Text] [Related]
2. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
[TBL] [Abstract][Full Text] [Related]
3. Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene.
Tamer F; Gulekon A
J Coll Physicians Surg Pak; 2021 Jun; 31(6):716-718. PubMed ID: 34102787
[TBL] [Abstract][Full Text] [Related]
4. CD4/CD8 double-negative T-cell lymphoma successfully treated with a combination of bexarotene and total skin electron beam therapy.
Tanigawa A; Fukumoto T; Imamura S; Nakamura K; Tanaka T; Itoh T; Nakano E; Nishigori C; Kubo A
J Dermatol; 2023 Jul; 50(7):e210-e212. PubMed ID: 36740368
[No Abstract] [Full Text] [Related]
5. The contribution of oligodendrocytes and oligodendrocyte progenitor cells to central nervous system repair in multiple sclerosis: perspectives for remyelination therapeutic strategies.
Dulamea AO
Neural Regen Res; 2017 Dec; 12(12):1939-1944. PubMed ID: 29323026
[TBL] [Abstract][Full Text] [Related]
6. Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.
Chamberlain KA; Nanescu SE; Psachoulia K; Huang JK
Neuropharmacology; 2016 Nov; 110(Pt B):633-643. PubMed ID: 26474658
[TBL] [Abstract][Full Text] [Related]
7. Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.
Rodgers JM; Robinson AP; Miller SD
Discov Med; 2013 Aug; 16(86):53-63. PubMed ID: 23911232
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection and repair in multiple sclerosis.
Franklin RJ; ffrench-Constant C; Edgar JM; Smith KJ
Nat Rev Neurol; 2012 Nov; 8(11):624-34. PubMed ID: 23026979
[TBL] [Abstract][Full Text] [Related]
9. Myelin regeneration in multiple sclerosis: targeting endogenous stem cells.
Huang JK; Fancy SP; Zhao C; Rowitch DH; Ffrench-Constant C; Franklin RJ
Neurotherapeutics; 2011 Oct; 8(4):650-8. PubMed ID: 21904791
[TBL] [Abstract][Full Text] [Related]
10. About the cutaneous targets of bexarotene in CTCL patients.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
[TBL] [Abstract][Full Text] [Related]
11. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
Guitart J
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
[TBL] [Abstract][Full Text] [Related]
13. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
14. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
15. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
